Luc Djoussé1, Chisa Matsumoto2, Naomi Q Hanson3, Natalie L Weir3, Michael Y Tsai3, J Michael Gaziano4. 1. Division of Aging, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; The Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC) and Geriatric Research (GRECC), Boston Veterans Affairs Healthcare System, Boston, MA, USA. Electronic address: ldjousse@rics.bwh.harvard.edu. 2. Division of Aging, Boston, MA, USA. 3. The University of Minnesota, Minneapolis, MN, USA. 4. Division of Aging, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; The Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC) and Geriatric Research (GRECC), Boston Veterans Affairs Healthcare System, Boston, MA, USA.
Abstract
BACKGROUND & AIMS: Although an inverse association of red blood cell cis-vaccenic acid and risk of myocardial infarction has been reported, it is unclear whether cis-vaccenic acid might lower the risk of heart failure (HF) with antecedent coronary heart disease (CHD). We sought to examine the relation of plasma cis-vaccenic acid with HF with antecedent CHD. METHODS: This nested case-control study was based on 788 incident HF cases (of whom 258 cases had antecedent CHD) and 788 controls. Each control was selected using a risk set sampling technique at the time of the occurrence of the index case and matched on year of birth, age at blood collection, and race. Fatty acids were measured using gas chromatography and incident HF was self-reported on annual questionnaires and validation in a subsample using medical records. RESULTS: In a multivariable conditional logistic regression, the odds ratio (95% confidence interval) for HF with prior CHD were 1.0 (ref), 0.72 (0.33-1.57), 0.28 (0.12-0.67), and 0.23 (0.09-0.58) across consecutive quartiles of cis-vaccenic acid (p_trend 0.0004). Each standard deviation of cis-vaccenic acid was associated with a 41% lower risk of HF with antecedent CHD (95% CI: 17%-59%) in a multivariable adjusted model. CONCLUSIONS: Our data suggest that higher plasma levels of plasma cis-vaccenic acid may be associated with a lower risk of HF with antecedent CHD. Confirmation of these results in the general population including women and other ethnic groups is warranted.
BACKGROUND & AIMS: Although an inverse association of red blood cell cis-vaccenic acid and risk of myocardial infarction has been reported, it is unclear whether cis-vaccenic acid might lower the risk of heart failure (HF) with antecedent coronary heart disease (CHD). We sought to examine the relation of plasma cis-vaccenic acid with HF with antecedent CHD. METHODS: This nested case-control study was based on 788 incident HF cases (of whom 258 cases had antecedent CHD) and 788 controls. Each control was selected using a risk set sampling technique at the time of the occurrence of the index case and matched on year of birth, age at blood collection, and race. Fatty acids were measured using gas chromatography and incident HF was self-reported on annual questionnaires and validation in a subsample using medical records. RESULTS: In a multivariable conditional logistic regression, the odds ratio (95% confidence interval) for HF with prior CHD were 1.0 (ref), 0.72 (0.33-1.57), 0.28 (0.12-0.67), and 0.23 (0.09-0.58) across consecutive quartiles of cis-vaccenic acid (p_trend 0.0004). Each standard deviation of cis-vaccenic acid was associated with a 41% lower risk of HF with antecedent CHD (95% CI: 17%-59%) in a multivariable adjusted model. CONCLUSIONS: Our data suggest that higher plasma levels of plasma cis-vaccenic acid may be associated with a lower risk of HF with antecedent CHD. Confirmation of these results in the general population including women and other ethnic groups is warranted.
Authors: Haiming Cao; Kristin Gerhold; Jared R Mayers; Michelle M Wiest; Steven M Watkins; Gökhan S Hotamisligil Journal: Cell Date: 2008-09-19 Impact factor: 41.582
Authors: Robert J Goldberg; Karen Glatfelter; Emma Burbank-Schmidt; Cheryl Farmer; Frederick A Spencer; Theo Meyer Journal: Am J Cardiol Date: 2005-06-01 Impact factor: 2.778
Authors: Dariush Mozaffarian; Haiming Cao; Irena B King; Rozenn N Lemaitre; Xiaoling Song; David S Siscovick; Gökhan S Hotamisligil Journal: Am J Clin Nutr Date: 2010-10-13 Impact factor: 7.045
Authors: Manu V Chakravarthy; Irfan J Lodhi; Li Yin; Raghu R V Malapaka; H Eric Xu; John Turk; Clay F Semenkovich Journal: Cell Date: 2009-07-30 Impact factor: 41.582
Authors: Allison M Hodge; Dallas R English; Kerin O'Dea; Andrew J Sinclair; Maria Makrides; Robert A Gibson; Graham G Giles Journal: Am J Clin Nutr Date: 2007-07 Impact factor: 7.045
Authors: Yujin Lee; Heidi T M Lai; Marcia C de Oliveira Otto; Rozenn N Lemaitre; Barbara McKnight; Irena B King; Xiaoling Song; Gordon S Huggins; Amanda R Vest; David S Siscovick; Dariush Mozaffarian Journal: J Am Heart Assoc Date: 2020-02-05 Impact factor: 5.501
Authors: Anne-Mari Mustonen; Reijo Käkelä; Antti Joukainen; Petri Lehenkari; Antti Jaroma; Tommi Kääriäinen; Heikki Kröger; Tommi Paakkonen; Sanna P Sihvo; Petteri Nieminen Journal: Biology (Basel) Date: 2021-05-04